Effect of switching to erenumab in non-responders to a CGRP ligand antibody treatment in migraine: A real-world cohort study

BACKGROUND: Therapeutic options for migraine prevention in non-responders to monoclonal antibodies (mAbs) targeting Calcitonin Gene-Related Peptide (CGRP) and its receptor are often limited. Real-world data have shown that non-responders to the CGRP-receptor mAb erenumab may benefit from switching t...

Descripción completa

Detalles Bibliográficos
Autores principales: Overeem, Lucas Hendrik, Lange, Kristin Sophie, Fitzek, Mira Pauline, Siebert, Anke, Steinicke, Maureen, Triller, Paul, Hong, Ja Bin, Reuter, Uwe, Raffaelli, Bianca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075077/
https://www.ncbi.nlm.nih.gov/pubmed/37034092
http://dx.doi.org/10.3389/fneur.2023.1154420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10075077/
https://www.ncbi.nlm.nih.gov/pubmed/37034092
http://dx.doi.org/10.3389/fneur.2023.1154420

Ejemplares similares